Compare Asana Inc. (ASAN) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs Heron Therapeutics Inc — how do they compare? Asana Inc. trades at $8.97 (market cap $2.13B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Asana Inc. is far larger — about 34.7× Heron Therapeutics Inc's market cap, and Asana Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ASAN | HRTX | |
|---|---|---|
Market Cap | $2.13B | $61.47M |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $1.49 |
52-Week Low | $5.46 | $0.32 |
Enterprise Value | $1.96B | $168.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $8.96, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth continues, reaching $723.88M in 2025, while net losses persist at -$255.54M. Recent Q1 2026 earnings beat expectations, and the company secured FedRAMP authorization and acquired StackAI to enhance AI capabilities, signaling strategic growth initiatives.
The outlook hinges on Asana's path to profitability amid high competition; analyst consensus is mixed with a $10.33 price target. Key risks include sustained losses and competitive pressure from larger tech firms, but AI product adoption and government contracts offer potential upside if execution improves.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
